In a first-of-its-kind collaboration between academia and industry, Pfizer Inc. will give scientists at the Washington University School of Medicine in St. Louis access to information on more than 500 pharmaceutical candidates. The partnership focuses on discovering new uses for existing compounds. “This is a tremendous opportunity for both partners,” says Jeffrey Gordon, MD, director of the University’s Center for Genome Sciences, in a FiercePharma release. “It leverages the complementary strengths and interests of both Washington University and Pfizer. By creating this innovative new framework, academic and pharmaceutical researchers can collaborate in ways that are mutually advantageous for the University, Pfizer and society to meet the needs of patients.” The agreement will address a broad range of diseases, including neurodegenerative disease.
Click here to read more.Share this: